

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

11068-078-999

APPLICATION NO

10/758,683

APPLICANT

Whitcomb, Jeannette

FILING DATE

January 14, 2004

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,436,131	7/95	Condra <i>et al.</i>			
	A02	5,631,128	5/97	Kozal <i>et al.</i>			
	A03	5,650,268	7/97	Kozal <i>et al.</i>			
	A04	5,837,464	11/98	Capon <i>et al.</i>			
	A05	5,917,033	6/99	Modak <i>et al.</i>			
	A06	6,033,902	3/00	Haseltine <i>et al.</i>			
	A07	6,103,462	8/00	Paulous <i>et al.</i>			
	A08	6,124,327	9/00	Silverman			
	A09	6,242,187	6/01	Capon <i>et al.</i>			
	A10	6,653,081	11/03	Whitcomb			
	A11	20040067487	4/04	Whitcomb			

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A12	WO99/67427	6/99	PCT				
	A13	WO99/61658	12/99	PCT				
	A14	WO02/22781	9/01	PCT				
	A15	International Search Report of PCT/US99/14486	6/99	PCT				
	A16	International Search Report of PCT/US01/28736	5/02	PCT				
	A17	International Search Report of PCT/US99/11629	9/99	PCT				
	A18	International Search Report of PCT/US01/18882	10/01	PCT				
	A19	Copy of International Search Report PCT/US03/21024	5/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A20	Ahluwalia, G. S., <i>et al.</i> (1996) "2', 3'-Didehydro-3'-deoxythymidine: Regulation of its Metabolic Activation by Modulators of Thymidine-5'-triphosphate Biosynthesis" <i>Mol. Pharm.</i> 50: 160-165
	A21	Appelt, <i>et al.</i> , (1991) "Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis," <i>J. Med. Chem.</i> 34: 1925-1934.
	A22	Arnold E., <i>et al.</i> (1995) "Structures of DNA and RNA Polymerases and Their Interactions with Nucleic Acid Substrates", <i>Curr Opin Struct Biol</i> 5:27-38;

A23	Back, KT, et al, (1996) "Reduce Replication of 3TC-Resistant HIV-1 Variants in Primary Cells Due to a Processivity Defect of the Reverse Transcriptase Enzyme", <i>EMBO</i> 15: 4040-4049
A24	Balzarini J, (1998) "A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures With the Nucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781" <i>AIDS Res. Human</i> , 14(3):255-260
A25	Balzarini J, et al. (1997) "Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Strains Subcultured in the of Both Lamivudine and Quinoxaline HBY 097 Retain Marked Sensitivity to HBY 097 but not to Lamivudine" <i>J of Infect Dis</i> , 176:1392-1397
A26	Balzarini J., et al., (1992) "HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity Against HIV1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase", <i>Virology</i> 192:246-253
A27	Barnes WM, (1994) "PCR Amplification of up to 35-kb DNA with High Fidelity and High Yield from I. Bacteriophage Templates" <i>PNAS</i> 91:2216-2220
A28	Bartenschlager R, et al, (1994) "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing", <i>J. Virol.</i> 68:5045-5055
A29	Boucher CAB, et al, (1993) "High-Level Resistance to (-) Enantiomeric 2'-Deoxy-3'-Thiacytidine In Vitro is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", <i>Antimicrob Agents Chemother</i> , 37:2231-2234
A30	Boucher CAB, et al, (1990) "Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy", <i>Lancet</i> 336:585-590
A31	Boyer, et al., "Analysis of Nucleoside Drug-Resistant Variants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>J. Virol.</i> , 67(4):2412-2420 (1993).
A32	Cheeseman S.H., et al. (1995) "Phase I/II Evaluation of Didanosine Alone and in Combination with Zidovudine for Infection with Human Immunodeficiency Virus", <i>J Acquir Immune Syndr</i> 8:141-151
A33	Coffin JM, (1995) "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy", <i>Science</i> 267:483-489
A34	Craig C and Moyle G, (1997) "The development of resistance of HIV-1 to zalcitabine", <i>AIDS</i> 11:271-279.
A35	Croteau G. et al (1997) "Impaired Fitness of Human Immunodeficiency Virus Type 1 Variants with High-Level Resistance to Protease Inhibitors" <i>J Virol</i> 71:1089-1096
A36	D'Aquila R.T. (1994) "Molecular Pathogenesis and Laboratory Monitoring", <i>Clin Lab Med</i> 14:393-423
A37	De Clercq E, (1997) "Development of Resistance of Human the 4); Immunodeficiency Virus (HIV) to Anti-HIV Agents: How to Prevent Problem" <i>Intl of Antimicrob Agents</i> , 9:21-36
A38	De Clercq E, (1992) "HIV Inhibitors Targeted at the Reverse Transcriptase", <i>AIDS Res. Hum Retrovir</i> 8:119-134
A39	DeJong, M.D., et al. (1994) "Alternating Nevirapine and Infected Zidovudine Treatment of Human Immunodeficiency Virus Type 1 Persons Does Not Prolong Nevirapine Activity", <i>J Infect Dis</i> 169:1346-1350
A40	DeJong MD, et al, (1996) "Host-parasite Dynamics and Outgrowth of Virus Containing a Single K70R Amino Acid Change in Reverse Transcriptase are Responsible for the Loss of Human Immunodeficiency Virus Type 1 RNA Load Suppression by Zidovudine", <i>PNAS</i> 93:5501-5506
A41	Descamps, et al., 1997 "Susceptibility of Human Immunodeficiency Virus Type 1 Group O Isolates to Antiretroviral Agents: In Vitro Phenotypic and Genotypic Analysis," <i>J. of Virology</i> 71(11): 8893-98.
A42	De Antoni A., et al. Mutations in a pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. <i>J. Infect Dis.</i> (1997) OCT.; 176(4): 899-903
A43	Doyon L, et al, (1996) "Second Locus Involved in Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors", <i>J Virol</i> 70:3763-3769
A44	Dueweke, T.J., et al. (1993) "A Mutation in Reverse to Other Transcriptase of Bis (Heteroaryl) Piperazine Resistant Human Immunodeficiency Virus Type 1. That Confers Increased Sensitivity; Nucleoside Inhibitors", <i>PNAS</i> 90:4713-4717
A45	Eastman, P. Scott, et al. (1995) Monoclonal Hybridization Assay for Determination of Relative Amounts of Genotypic Human Immunodeficiency Virus Type 1 Zidovudine Resistance", <i>J Clin</i> 2777-2780
A46	Fitzgibbon et al. Human Immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. <i>Journal of Virology</i> , vol. 67, No. 12 (1993) pp. 7271-7275.
A47	Frenkel et al. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. <i>Journal of Clinical Immunology</i> . vol. 33, No. 2 (1995) pp. 342-347.
A48	Frost, S.D.W., and McLean, A.R. (1994) "Quasispecies Dynamics and the Emergence of Drug Resistance During Zidovudine Therapy of HIV Infection", <i>AIDS</i> 8:323-332.
A49	Gerondelis P, et al, (1999) "The P236L Didanosine-Resistant Human Immunodeficiency Virus Type 1 Mutant is Replication Defective and Demonstrates Alterations in both RNA 5'-End-and DNA 3',-End-Directed RNase H Activities", <i>J Virol.</i> 73: 5803-5813
A50	Gervais, et al., "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility in Vitro", <i>Proc. Natl. Acad. Sci. USA</i> (1997), Vol. 94 pgs 4653-4658.

2	A51	Goulden MG, et al, (1996) "Selection In Vitro of an HIV-1 Variant Resistant to Both Lamivudine (3TC) and Zidovudine", AIDS 10:101-102.
	A52	Gu Z, et al, (1994) "Identification of Novel Mutations that Confer Drug Resistance In the Human Immunodeficiency Virus Polymerase Gene", Leukemia 8(1):166-169.
	A53	Hammond, et al., 1998 "Mutations in Retroviral Genes Associated with Drug Resistance," 36-79.
	A54	Harrigan PR, et al, (1998) "Relative Replication Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro", J Virol. 72:3773-3778
	A55	Ho DD, et al, (1994) "Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to a C2-Symmetric Protease Inhibitor", J Virol 68:2016-2020
	A56	Holodniy, Mark, et al. (1995) "Determination of Human Immunodeficiency Virus RNA In Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance Combination Therapy", J Virol, 3510-3516
	A57	Hazuda, et al., 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells," Science 287: 646-650.
	A58	Herrmann, et al., "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity", Ann. NY Acad Sciences (1997), 284: 632-637.
	A59	Hertogs, et al., "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs", Antimicrobial Agents and Chemotherapy (1998) 42(2): 269-276.
	A60	Iversen et al. "Multidrug-resistant immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy," Journal of Virology. vol. 70, No. 2 (1996) pp. 1086-1090.
	A61	Kellam, P., et al. (1994) "Zidovudine Treatment Results in the Selection of Human Immunodeficiency Virus Type 1 Variants Whose Genotypes Confer Increasing Levels of Drug Resistance", J Gen Virol 75:341-351.
	A62	Kim EE, et al, (1995) "Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme", J Am Chem Soc. 117: 1181-1182
	A63	Kleim, J., et al. (1997) "In vitro Selection for Different Mutational Patterns in the HIV-1 Reverse Transcriptase Using High and Low Selective Pressure of the Nonnucleoside Reverse Transcriptase inhibitor HBY 097" Virology. 231: 112-118
	A64	Kosalaraksa P, et al, (1999) "Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay", J Virol 73:5356-5363.
	A65	Krebs, R., et al. 1997 "Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC" Biochemistry 36: 10292-10300
	A66	Kuritzkes D.R. Clinical significance of drug resistance in HIV-1 infection. AIDS (1996) vol. 10, S27-S31.
	A67	Larder BA, (1992) "3'-Azido-3'-Deoxythymidine Resistance Suppressed by a Mutation Conferring Human Immunodeficiency Virus Type 1 Resistance to Nonnucleoside Reverse Transcriptase Inhibitors", Antimicrob Agents Chemother 36: 2664-2669.
	A68	Larder BA, et al, (1991) "Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes", AIDS 5:137-144.
	A69	Larder BA, et al, (1995) "Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy", Science 269:696-699.
	A70	Lie, et al., "Advances In Quantitative PCR Technology: 5' Nuclease Assays", Curr Opinion Biotech (1998), 9(1): 43-48.
	A71	Lieven Stuyver, et al. (1997) "Line Probe Assay For Rapid Detection Of Drug Selected Mutations In The Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene", Antimicrob Agents and Chemother, 284-291
	A72	Lin PF, et al, (1994) "Genotypic and Phenotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from Patients on Prolonged Stavudine Therapy", J Infect Disease 170:1157-1164.
	A73	Lopez-Galindez C, et al, (1991) "Characterization of genetic variation and 3'-azido-3'-deoxythymidine-resistance mutations of human immunodeficiency virus by the RNAase A mismatch cleavage method", PNAS 88:4280-4284.
	A74	Mammamo F, et al, (1998) "Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease and gag Coevolution in Protease Inhibitor-Treated Patients", J Virol 72:7632-7637
	A75	Maschera B, et al, (1996) "Mutations in the Viral Protease that Confer Resistance to Saquinavir Increase the Dissociation Rate Constant of the Protease-Saquinavir Complex", Bio Chem 271:33231-33235.
	A76	Mayers DL, et al, (1992) "Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy", J Acq Imm Def Synd 5:749-759
	A77	Moyle GJ (1996) "Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimizing Selection of Drug Combinations and Sequences", Drugs 52:168-185
	A78	Mohri, H., et al. (1993) "Quantitation of Zidovudine Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients", PNAS 90:25-29

A79	Mulligan RC and Berg P, (1980) "Expression of a Bacterial Gene in Mammalian Cells", <i>Science</i> 209:1422-11427
A80	Nájera, I., <i>et al.</i> (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates", <i>Aids Res Hum Retroviruses</i> 10:1479-1488
A81	Nájera, I., <i>et al.</i> (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in virus from Patients Undergoing No Drug Therapy", <i>J Virol</i> 69:23-31
A82	Nijhuis, <i>et al.</i> , "Implications of Antiretroviral Resistance on Viral Fitness", <i>Curr. Opin. Infect Diseases</i> (2001), 14: 23-28.
A83	Nunberg, J.H., <i>et al.</i> (1990) "Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors", <i>J Virol</i> 65:4887-4892
A84	Pelemans H, <i>et al.</i> (1997) "Characteristics of the Pro225His Mutation in Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase That Appears Under Selective Pressure of Dose Escalating Quinoxaline Treatment of HIV-1" <i>J. Virol.</i> , 71(11) :8195-8203
A85	Petropoulos, <i>et al.</i> , "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1", <i>Antimicrobial Agents and Chemotherapy</i> (2000), 44(4): 920-928.
A86	Race, <i>et al.</i> , "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies", <i>AIDS</i> (1999), 13(15): 2061-2068.
A87	Richman, D.D. <i>et al.</i> (1994) "Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy", <i>J Virol</i> 68:1660-1666
A88	Richman, D.D. <i>et al.</i> (1991) "Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture", <i>PNAS</i> 88:11241-11245
A89	Sanger, <i>et al.</i> (1977) "DNA Sequencing with Chain-terminating Inhibitors", <i>PNAS</i> 88: 11241-245.
A90	Sakar, G. and Sommer, S.S. (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis" <i>Biotech</i> , 8(4):404-407
A91	Sanger, <i>et al.</i> (1977) "DNA Sequencing with Chain-terminating Inhibitors", <i>PNAS</i> 88: 11241-245.
A92	Shafer RW, <i>et al.</i> (1994) "Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene Mutations", <i>J Infect Disease</i> 169:722-729
A93	Shi, <i>et al.</i> , "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors", <i>Antimicrobial Agents and Chemotherapy</i> (1997) 41(12): 2781-85.
A94	Shirasaka T, <i>et al.</i> (1995) "Emergence of Human Immunodeficiency Virus Type 1 Variants with Resistance to Multiple Deoxynucleosides in Patients Receiving Therapy with Dideoxynucleosides", <i>PNAS</i> 92:2398-2402
A95	Southern, <i>et al.</i> (1982) "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", <i>Appl. Genet</i> 1:327-341
A96	Strair RK, <i>et al.</i> (1993) "Recombinant Retroviral Systems For the Analysis of Drug Resistant HIV" <i>Nucl Acids Res</i> , 21(20): 4836-4842
A97	Sugden B, <i>et al.</i> (1985) "A Vector that Replicates as a Plasmid and can be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus", <i>Mol Cell Bio</i> 5:410-413.
A98	Tisdale M, <i>et al.</i> (1993) "Rapid In Vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors due to a Mutation in the YMDD Region of Reverse Transcriptase", <i>PNAS</i> 90:5653-5656.
A99	Vacca JP, <i>et al.</i> (1994) "L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor", <i>PNAS</i> 91:4096-4100.
A100	Villahermosa, ML, <i>et al.</i> "Evaluations of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors" <i>Antiviral Ther.</i> (1998); 3(4):221-227
A101	Zennou V, (1998) "Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo", <i>J. Virol.</i> , 72:3300-3306.
A102	Zhang Y, <i>et al.</i> (1997) "Drug Resistance During Indinavir Therapy is Caused by Mutations in the Protease Gene and in its Gag Substrate Cleavage Sites", <i>J Virol</i> 71:6662-6670.
A103	Zhang D, <i>et al.</i> (1994) "Resistance to 2',3'-Dideoxycytidine Conferred by a Mutation in Codon 65 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase", <i>Antimicrob Agents Chemother</i> 38:282-287
EXAMINER 	
DATE CONSIDERED 03/05/07	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO.
011068-078-999	10/758,683
APPLICANT	
Whitcomb, Jeanette	
FILING DATE	GROUP
January 14, 2004	1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO97/27332	7/97	PCT				
	B02	WO97/27319	7/97	PCT				
	B03	European Search Report for EP 0194452	10/04	EPO				
	B04	European Search Report for EP 99933581	9/04	EPO				
	B05	European Search Report for EP 99925874	9/04	EPO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	B06	Buckheit, <i>et al.</i> (1995) "Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine Derivatives is Generated by Mutations at Multiple Sites in the HIV-1 Reverse Transcriptase", <i>Virology</i> 210(1):186-193.
	B07	Esnouf, <i>et al.</i> (1997) "Unique Features in the Structure of the Complex Between HIV-1 Reverse Transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 Explain Resistance Mutations for this Nucleoside Inhibitor", <i>PNAS</i> 94(8) 3984-3989.
	B08	Fan <i>et al.</i> 1995 "Mechanism of Resistance to U-90152S and Sensitization to L-697, 661 by a Proline to Leucine Change at Residue 236 of Human Immunodeficiency Virus Type-1 (HIV-1) Reverse Transcriptase", <i>FEBS Letters</i> 359(2-3): 233-238.
	B09	Kanki, <i>et al.</i> (1997) "Virology of HIV-1 and HIV-2: Implications for Africa", <i>AIDS</i> 11(Supp. B): S33-S42.
	B10	Mellors, <i>et al.</i> (1995) "Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance", <i>International Antiviral News Volume</i> 3: 8-13.
	B11	Romero, <i>et al.</i> (1996) "Targeting Delavirdine/Ateviridine Resistant HIV-1: Identification of Piperidine-Containing bis(heteroaryl) piperazines as Broad Spectrum HIV-1 Reverse Transcriptase Inhibitors", <i>Journal of Medicinal Chemistry</i> 33(19) 3769-3789.
	B12	Salomon, <i>et al.</i> (2000) "Prevalence of HIV-1 Resistant to Antiretroviral Drugs in 81 Individuals Newly Infected By Sexual Contact or Injecting Drug Use", <i>AIDS (London, England)</i> 14(2): F17-F23.

EXAMINER

DATE CONSIDERED

03/05/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.